Medical Properties Trust Q3 revenue rises

By Reuters News


Overview

  • U.S. hospital real estate trust's Q3 revenue missed analyst expectations, but rose yr/yr

  • Net income for Q3 returned to profit from loss in prior year

  • Company completed asset sales and debt refinancing, generating $680 mln in proceeds and gains


Outlook

  • Company expects portfolio cash rents above $1.0 bln in 2027

  • Company outlook assumes conservative estimates for rental income from challenged tenants such as HSA

  • Company says it is focused on further debt reduction and selective growth opportunities


Result Drivers

  • ASSET SALES - Co said asset sales in Q3 generated $680 mln in proceeds and $158 mln in gains

  • DEBT REFINANCING - Co said refinancing of debt via secured notes offering resulted in $70 mln gain

  • TENANT PAYMENT ISSUES - Co said missed rent payment from HSA reduced NFFO by two cents in Q3


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$250.14 mln

$257.98 mln (6 Analysts)

Q3 Net Income

$202.08 mln


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 3 "hold" and 2 "sell" or "strong sell"

  • The average consensus recommendation for the specialized reits peer group is "buy."

  • Wall Street's median 12-month price target for Medical Properties Trust, Inc. is $5.00, about 81.8% above its October 28 closing price of $2.75


Reuters Recommended Reads

  • Oct 26 - Alexandria Real Estate Q3 net loss widens on impairments

  • Oct 27 - Universal Health Realty Income Trust Q3 profit rises, helped by lower interest costs

  • Oct 27 - WP Carey Q3 revenue beats estimates, raises annual AFFO forecast on strong investment activity


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.